BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO - New York Stock Exchange, Inc. - US0905722072 - Common Stock - Currency: USD
Overall BIO gets a fundamental rating of 5 out of 10. We evaluated BIO against 54 industry peers in the Life Sciences Tools & Services industry. While BIO has a great health rating, its profitability is only average at the moment. BIO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BIO had positive earnings in the past year.
BIO had a positive operating cash flow in the past year.
In multiple years BIO reported negative net income over the last 5 years.
Each year in the past 5 years BIO had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 3.12%, BIO is doing good in the industry, outperforming 74.07% of the companies in the same industry.
BIO has a better Return On Equity (4.47%) than 74.07% of its industry peers.
BIO has a Return On Invested Capital of 2.36%. This is in the better half of the industry: BIO outperforms 61.11% of its industry peers.
BIO had an Average Return On Invested Capital over the past 3 years of 2.69%. This is significantly below the industry average of 16.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROIC | 2.36% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
The Profit Margin of BIO (12.49%) is better than 85.19% of its industry peers.
Looking at the Operating Margin, with a value of 11.30%, BIO is in the better half of the industry, outperforming 68.52% of the companies in the same industry.
BIO's Operating Margin has been stable in the last couple of years.
The Gross Margin of BIO (53.00%) is better than 62.96% of its industry peers.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
BIO has less shares outstanding than it did 5 years ago.
BIO has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.14 indicates that BIO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.14, BIO is in the better half of the industry, outperforming 64.81% of the companies in the same industry.
The Debt to FCF ratio of BIO is 3.46, which is a good value as it means it would take BIO, 3.46 years of fcf income to pay off all of its debts.
BIO has a Debt to FCF ratio of 3.46. This is in the better half of the industry: BIO outperforms 72.22% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that BIO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.17, BIO perfoms like the industry average, outperforming 57.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 3.14 |
ROIC/WACC0.24
WACC9.92%
2.3 Liquidity
BIO has a Current Ratio of 5.12. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO has a better Current ratio (5.12) than 72.22% of its industry peers.
BIO has a Quick Ratio of 3.67. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.67, BIO is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.11%.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
The Revenue has decreased by -0.33% in the past year.
Measured over the past years, BIO shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
3.2 Future
Based on estimates for the next years, BIO will show a decrease in Earnings Per Share. The EPS will decrease by -4.33% on average per year.
The Revenue is expected to grow by 1.35% on average over the next years.
EPS Next Y-17.35%
EPS Next 2Y-4.67%
EPS Next 3Y1.5%
EPS Next 5Y-4.33%
Revenue Next Year-2.19%
Revenue Next 2Y0.57%
Revenue Next 3Y1.77%
Revenue Next 5Y1.35%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BIO is valuated quite expensively with a Price/Earnings ratio of 27.51.
Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 70.37% of the companies in the same industry.
BIO is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.24, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 29.54, BIO can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 36.42. BIO is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.51 | ||
| Fwd PE | 29.54 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO is valued a bit cheaper than 77.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.67 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The decent profitability rating of BIO may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.51
EPS Next 2Y-4.67%
EPS Next 3Y1.5%
5. Dividend
5.1 Amount
No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
276.8
-7.8 (-2.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.78%
Inst Owner Change-1.31%
Ins Owners3.67%
Ins Owner Change0%
Market Cap7.53B
Analysts76.36
Price Target320.79 (15.89%)
Short Float %4.82%
Short Ratio2.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.02%
Min EPS beat(2)38.97%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)40.05%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)26.32%
EPS beat(12)8
Avg EPS beat(12)16.87%
EPS beat(16)12
Avg EPS beat(16)20.5%
Revenue beat(2)2
Avg Revenue beat(2)2.99%
Min Revenue beat(2)1.11%
Max Revenue beat(2)4.87%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-1.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.6%
Revenue beat(16)6
Avg Revenue beat(16)-0.34%
PT rev (1m)-0.26%
PT rev (3m)-10.1%
EPS NQ rev (1m)-1.25%
EPS NQ rev (3m)-30.61%
EPS NY rev (1m)-1.39%
EPS NY rev (3m)-12.45%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-3.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.51 | ||
| Fwd PE | 29.54 | ||
| P/S | 2.95 | ||
| P/FCF | 21.67 | ||
| P/OCF | 14.09 | ||
| P/B | 1.06 | ||
| P/tB | 1.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.06
EY3.63%
EPS(NY)9.37
Fwd EY3.38%
FCF(TTM)12.77
FCFY4.61%
OCF(TTM)19.65
OCFY7.1%
SpS93.87
BVpS261.99
TBVpS226.03
PEG (NY)N/A
PEG (5Y)3.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROCE | 2.99% | ||
| ROIC | 2.36% | ||
| ROICexc | 2.75% | ||
| ROICexgc | 3.12% | ||
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% | ||
| FCFM | 13.61% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score6
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | -6.2 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 108.94% | ||
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 3.14 |
F-Score6
WACC9.92%
ROIC/WACC0.24
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
EPS Next Y-17.35%
EPS Next 2Y-4.67%
EPS Next 3Y1.5%
EPS Next 5Y-4.33%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
Revenue Next Year-2.19%
Revenue Next 2Y0.57%
Revenue Next 3Y1.77%
Revenue Next 5Y1.35%
EBIT growth 1Y-15.48%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year22.43%
EBIT Next 3Y13.71%
EBIT Next 5Y6.41%
FCF growth 1Y125.65%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y86.4%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%